Edison Investment Research
Summary
- The recent increasing adoption of GLP-1 drugs has fundamentally changed the landscape of weight loss and health habits.
- The GLP-1 user population is moving away from nutritionally poor foods and towards higher protein, smaller portion, and nutrient-dense options.
- While supermarket chains and nutritionally oriented retailers are finding success in adapting their products in accordance with consumer demand, the fitness sector is also gaining from such a market tailwind.
- Using GLP-1s may appear as a fast-track method to achieving weight-loss goals, but like most fitness and nutrition programmes, persistence is key to success.
Why are the GLP-1 drugs having an effect on consumer behaviour?
The recent increasing adoption of GLP-1 drugs has fundamentally changed the landscape of weight loss and health habits. Prescription medicines such as Ozempic, Wegovy, and Mounjaro
Edison Investment Research
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
